This article aims to determine the serological biomarkers which can be considered as risk factors of systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension by a systematic review and meta-analysis.
Methods
This study was conducted in accordance with the PRISMA statement. The search database included MEDLINE, EMBASE, Cochrane Library and Scopus. The Newcastle–Ottawa scale was used for the quality assessment. The odds ratio was the primary measure of effect of the risk factors.
Results
Twelve studies were included in this meta-analysis. The results identified the anti-RNP antibody and anti-Sm antibody as risk factors for SLE-associated pulmonary arterial hypertension with the pooled odds ratios 3.68 (95% confidence interval 2.04–6.63, P < 0.0001) and 1.71 (95% confidence interval 1.06–2.76, P = 0.03), respectively.
Conclusion
Pulmonary arterial hypertension is a serious complication of SLE with a worse prognosis than SLE patients without pulmonary arterial hypertension. The early recognition of pulmonary arterial hypertension with transthoracic echocardiography routinely performed in SLE patients with risk factors is necessary, especially in Asian patients.
WinslowTMOssipovMAFazioGPet al.Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J1995; 129: 510–515.
6.
JohnsonSRGladmanDDUrowitzMBIbanezDGrantonJT. Pulmonary hypertension in systemic lupus. Lupus2004; 13: 506–509.
7.
LuoRQLeiYXZhangXLiangF. [Clinical analysis of patients with systemic lupus erythematosus and concomitant pulmonary hypertension]. Nan Fang Yi Ke Da Xue Xue Bao2008; 28: 1860–1863.
8.
LiMWangQZhaoJet al.Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus2014; 23: 1085–1091.
9.
DoriaAGattoMZenMIaccarinoLPunziL. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev2014; 13: 770–777.
10.
MakACheungMWChiewHJLiuYHoRC. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum2012; 41: 830–839.
11.
QianJWangYHuangCet al.Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: a PRISMA-compliant systematic review and meta-analysis. Autoimmun Rev2016; 15: 250–257.
12.
ShenMWangYXuWBZengXJZhangFC. [Pleuropulmonary manifestations of systemic lupus erythematosus]. Zhonghua Yi Xue Za Zhi2005; 85: 3392–3395.
13.
MinHKLeeJHJungSMet al.Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival. Korean J Intern Med2015; 30: 232–241.
14.
MensahKAYadavRTrowTKBrunetCMFaresWH. Lupus-associated pulmonary arterial hypertension: variable course and importance of prompt recognition. Case Rep Med2015; 2015: 328435–328435.
15.
KamelSROmarGMDarwishAFAsklanyHTEllabbanAS. Asymptomatic pulmonary hypertension in systemic lupus erythematosus. Clin Med Insights Arthritis Musculoskelet Disord2011; 4: 77–86.
RobbinsIMGaineSPSchilzRet al.Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest2000; 117: 14–18.
18.
JaisXLaunayDYaiciAet al.Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum2008; 58: 521–531.
19.
TanakaEHarigaiMTanakaMet al.Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol2002; 29: 282–287.
20.
HuangCZhangSTianZLiMZengX. Could pulmonary arterial hypertension be an active index of systemic lupus erythematosus? A successful case of SLE–PAH cured by methylprednisolone pulse therapy. Lupus2014; 23: 1533–1536.
21.
JohnsonSRGrantonJT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev2011; 20: 277–286.
22.
LiberatiAAltmanDGTetzlaffJet al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ2009; 339: b2700–b2700.
23.
TanEMCohenASFriesJFet al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
24.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
25.
PetriMOrbaiAMAlarconGSet al.Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
26.
GalieNHoeperMMHumbertMet al.Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J2009; 30: 2493–2537.
27.
DimitroulasTGiannakoulasGDimitroulaHet al.Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. Rheumatol Int2011; 31: 263–267.
28.
Castillo-MartinezDMarroquin-FabianELozada-NavarroACet al.Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: a seven-year follow-up study. Lupus2016; 25: 61–66.
SavaleLTuLRideauDet al.Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res2009; 10: 6–6.
31.
KimKJBaekIWYoonCHKimWUChoCS. Association of anemic hypoxia and increased pulmonary artery systolic pressure in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken)2015; 67: 1702–1711.
32.
GuoLLiMChenYet al.Anti-endothelin receptor type A autoantibodies in systemic lupus erythematosus-associated pulmonary arterial hypertension. Arthritis Rheumatol2015; 67: 2394–2402.
33.
WangZWangYZhuRet al.Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies. Medicine (Baltimore)2015; 94: e794–e794.
34.
HuangCLiMLiuYet al.Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients. Medicine (Baltimore)2016; 95: e2761–e2761.
35.
PlastirasSCKaradimitrakisSPKampolisCMoutsopoulosHMTzelepisGE. Determinants of pulmonary arterial hypertension in scleroderma. Semin Arthritis Rheum2007; 36: 392–396.
36.
KasparianAFlorosAGialafosEet al.Raynaud’s phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus2007; 16: 505–508.
37.
TangXHuangYDengWet al.Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: a retrospective review of 917 patients in South China. Medicine (Baltimore)2010; 89: 62–67.
38.
LuRRobertsonJMBrunerBFet al.Multiple autoantibodies display association with lymphopenia, proteinuria, and cellular casts in a large, ethnically diverse SLE patient cohort. Autoimmune Dis2012; 2012: 819634–819634.
39.
LiJLengXLiZet al.Chinese SLE treatment and research group registry: III. Association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus. J Immunol Res2014; 2014: 809389–809389.
40.
LeeJHIm ChoK. Arterial stiffness, antiphospholipid antibodies, and pulmonary arterial hypertension in systemic lupus erythematosus. J Cardiol2014; 64: 450–455.
41.
CiangCOChanPSLeungMH. Systemic lupus erythematosus-associated pulmonary hypertension: clinical variables and survival outcome. Int J Clin Rheumatol2015; 10: 149–160.
42.
KimKJBaekIWParkYJet al.High levels of uric acid in systemic lupus erythematosus is associated with pulmonary hypertension. Int J Rheum Dis2015; 18: 524–532.
43.
LianFChenDWangYet al.Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int2012; 32: 1727–1731.
44.
PrabuAPatelKYeeCSet al.Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford)2009; 48: 1506–1511.
45.
Farzaneh-FarARomanMJLockshinMDet al.Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum2006; 54: 3918–3925.
46.
FoisELe GuernVDupuyAet al.Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. Clin Exp Rheumatol2010; 28: 836–841.
47.
Ruiz-IrastorzaGGarmendiaMVillarIEgurbideMVAguirreC. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev2013; 12: 410–415.
48.
MukerjeeDSt GeorgeDKnightCet al.Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford)2004; 43: 461–466.
49.
HsuVMMoreyraAEWilsonACet al.Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol2008; 35: 458–465.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
